In vivo virology core
体内病毒学核心
基本信息
- 批准号:10512625
- 负责人:
- 金额:$ 376.07万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-05-16 至 2025-04-30
- 项目状态:未结题
- 来源:
- 关键词:2019-nCoVAddressAnimal ModelAntiviral resistanceBunyaviralesCanadaClinical TrialsCoronavirusDengue VirusDevelopmentDiseaseDoseDrug CombinationsDrug resistanceEnterovirusEpidemicFamilyFamily PicornaviridaeFlavivirusFutureGenerationsGenetic VariationGoalsHumanImmunization ProgramsIn VitroInstitutesLaboratoriesLeadLettersMaximum Tolerated DoseMicrobiologyMorbidity - disease rateMusMutationOralOrthobunyavirusOutpatientsParis, FrancePatientsPatternPharmaceutical ChemistryPlayProphylactic treatmentPublic HealthRNA VirusesRNA-Directed RNA PolymeraseReaction TimeResearch PersonnelResistanceResistance profileRiskRoleSARS-CoV-2 antiviralSARS-CoV-2 variantSafetyStudy modelsSupervisionTestingTherapeuticTimeTogaviridaeToxic effectTreatment EfficacyVaccinesViralVirusVirus DiseasesVirus InhibitorsVirus ReplicationWorkZoonosesanti-viral efficacyantiviral drug developmentclinical developmentcoronavirus diseasedisabilitydrug candidatedrug discoveryemerging pathogenexperienceexperimental studyfitnesshuman pathogenimprovedin vitro activityin vivoin vivo evaluationindustry partnerinfluenzaviruslead optimizationmedical schoolsmortalitymouse modelpandemic diseasepathogenprogramsrational designresistance mutationresponsetransmission processvariants of concernviral fitnessviral resistancevirologyweapons
项目摘要
CORE 7: IN VIVO VIROLOGY
SUMMARY
SARS-CoV-2 continues to cause severe morbidity and mortality in the current pandemic, and future RNA virus
epidemics or pandemics are inevitable. To improve patient mortality rates, the development of antiviral
therapeutics is critical. However, currently available SARS-CoV-2 antiviral treatments are limited in efficacy.
Furthermore, it is imperative that we have access to an arsenal of compounds against all RNA viruses of
pandemic potential ready to be deployed into clinical trials at the earliest stages of future pandemics to save
millions of lives and reduce long-term disabilities associated with disease.
The goal of the QCRG Pandemic Response Program is the identification and development of oral drug
candidates with suitable safety profiles for broad use in the outpatient setting. The In Vivo Virology Core plays
an essential role in the QCRG Drug Discovery Platform in the Hit-to-Lead and Lead Optimization stages, working
closely with Projects 1-6 and the In Vitro Virology and Medicinal Chemistry Cores. Our goal is to determine
the therapeutic efficacy of antiviral hits and leads against coronaviruses, flaviviruses, togaviruses, picornaviruses
and Bunyavirales in advanced animal models of viral infection.
We have assembled a team of investigators with decades of experience in advanced animal models for the
analysis of antiviral countermeasures against the target viral families. We will first analyze hit compounds in
animal models using single concentration prophylactic treatment of maximal tolerated dose. Compounds that
show antiviral activity against viruses in vitro (established by the In Vitro Virology core) and have a favorable
PK and toxicity profile in vivo (Medicinal Chemistry Core), will be tested for their ability to inhibit viral replication
and disease in mice challenged with coronaviruses, flaviviruses, enteroviruses, togaviruses, and bunyaviruses.
For compounds with antiviral activity in vivo in single-dose treatments, we will determine dose responses, time
of administration post-challenge for therapeutic activity, and spectrum of activity against multiple strains and
viruses (Aim 1). We expect to identify 8-12 or 8-10 Lead Compounds for coronaviruses and other pandemic-
potential RNA viruses, respectively. Next, in Aim 2, we will determine antiviral resistance patterns and fitness of
resistant mutantsIn addition, beneficial compound combinations identified in vitro (In Vitro Virology Core), will
be tested in drug combinations studies in the appropriate animal model, both with known virus inhibitors and with
each other. We anticipate being a key component for antiviral development and expect to iterate with Projects
and Cores to obtain 3-6 Optimized Leads that will be transferred to our industry partner Roche for clinical
development.
核心 7:体内病毒学
概括
SARS-CoV-2 在当前的大流行中继续造成严重的发病率和死亡率,而未来的 RNA 病毒
流行病或流行病是不可避免的。为了降低患者死亡率,抗病毒药物的开发
治疗至关重要。然而,目前可用的 SARS-CoV-2 抗病毒治疗效果有限。
此外,我们必须获得针对所有 RNA 病毒的化合物库。
大流行的潜力已准备好在未来大流行的最早阶段部署到临床试验中,以挽救生命
数百万人的生命并减少与疾病相关的长期残疾。
QCRG 流行病应对计划的目标是识别和开发口服药物
具有适当安全性的候选者,可在门诊环境中广泛使用。体内病毒学核心
在 QCRG 药物发现平台的 Hit-to-Lead 和 Lead Optimization 阶段发挥着重要作用,
与项目 1-6 以及体外病毒学和药物化学核心密切合作。我们的目标是确定
抗病毒药物对冠状病毒、黄病毒、披膜病毒、小核糖核酸病毒的治疗效果
和布尼亚病毒目在病毒感染的高级动物模型中的应用。
我们组建了一支在先进动物模型方面拥有数十年经验的研究人员团队
针对目标病毒家族的抗病毒对策分析。我们将首先分析中的热门化合物
动物模型使用最大耐受剂量的单一浓度预防性治疗。化合物
在体外表现出抗病毒活性(由体外病毒学核心建立)并具有良好的
体内 PK 和毒性特征(药物化学核心)将测试其抑制病毒复制的能力
以及受到冠状病毒、黄病毒、肠道病毒、披膜病毒和布尼亚病毒攻击的小鼠的疾病。
对于单剂量治疗中具有体内抗病毒活性的化合物,我们将确定剂量反应、时间
攻击后的治疗活性和针对多种菌株的活性谱和
病毒(目标 1)。我们期望识别冠状病毒和其他流行病的 8-12 或 8-10 先导化合物
分别是潜在的RNA病毒。接下来,在目标 2 中,我们将确定抗病毒耐药模式和适应性
此外,体外鉴定的有益化合物组合(体外病毒学核心)将
在适当的动物模型中进行药物组合研究测试,包括已知的病毒抑制剂和
彼此。我们预计成为抗病毒开发的关键组成部分,并期望与项目进行迭代
和核心以获得 3-6 个优化的先导化合物,这些先导化合物将转移给我们的行业合作伙伴罗氏进行临床
发展。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Adolfo Garcia-Sastre其他文献
Adolfo Garcia-Sastre的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Adolfo Garcia-Sastre', 18)}}的其他基金
A deep longitudinal analysis of next generation influenza vaccines in older adults
对老年人使用下一代流感疫苗的深入纵向分析
- 批准号:
10544172 - 财政年份:2022
- 资助金额:
$ 376.07万 - 项目类别:
Immune phenotyping of responses to influenza virus vaccination and infection
流感病毒疫苗接种和感染反应的免疫表型
- 批准号:
10595642 - 财政年份:2022
- 资助金额:
$ 376.07万 - 项目类别:
A deep longitudinal analysis of next generation influenza vaccines in older adults
对老年人使用下一代流感疫苗的深入纵向分析
- 批准号:
10342393 - 财政年份:2022
- 资助金额:
$ 376.07万 - 项目类别:
Immune phenotyping of responses to influenza virus vaccination and infection
流感病毒疫苗接种和感染反应的免疫表型
- 批准号:
10435237 - 财政年份:2022
- 资助金额:
$ 376.07万 - 项目类别:
Development of CoV inhibitors against non-enzymatic targets
针对非酶靶标的 CoV 抑制剂的开发
- 批准号:
10514327 - 财政年份:2022
- 资助金额:
$ 376.07万 - 项目类别:
Vulnerability of SARS- CoV-2 Infection in Lung Cancer Based on Serological Antibody Analyses
基于血清学抗体分析的 SARS-CoV-2 感染对肺癌的脆弱性
- 批准号:
10222305 - 财政年份:2020
- 资助金额:
$ 376.07万 - 项目类别:
Vulnerability of SARS- CoV-2 Infection in Lung Cancer Based on Serological Antibody Analyses
基于血清学抗体分析的 SARS-CoV-2 感染对肺癌的脆弱性
- 批准号:
10706729 - 财政年份:2020
- 资助金额:
$ 376.07万 - 项目类别:
Vulnerability of SARS- CoV-2 Infection in Lung Cancer Based on Serological Antibody Analyses
基于血清学抗体分析的 SARS-CoV-2 感染对肺癌的脆弱性
- 批准号:
10688370 - 财政年份:2020
- 资助金额:
$ 376.07万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 376.07万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 376.07万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 376.07万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 376.07万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 376.07万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 376.07万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 376.07万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 376.07万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 376.07万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 376.07万 - 项目类别:
Research Grant














{{item.name}}会员




